Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of GSP 301 in Seasonal Allergic Rhinitis
NCT02318303Phase 2Completed
- Sponsor
- Glenmark Pharmaceuticals
- Start
- Dec 2014
- Primary completion
- Feb 2015
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mometasone in seasonal allergic rhinitis (SAR) (7 arms), sponsored by Glenmark Pharmaceuticals. Primary endpoint: Reflective Total Nasal Symptom Score at 14 days. Started Dec 2014; status: completed.
02
Drugs
mometasone
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT02318303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02318303.